Items where authors include "Ritchlin, C"

Article

Smolen, JS, Schöls, M, Braun, J et al. (34 more authors) (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 77 (1). pp. 3-17. ISSN 0003-4967

Gossec, L, Smolen, JS, Gaujoux-Viala, C et al. (32 more authors) (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases, 71 (1). pp. 4-12. ISSN 0003-4967

Conference or Workshop Item

Rahman, P, Ritchlin, C, Mease, P et al. (10 more authors) (2022) Long-term Safety of Guselkumab in Patients With Active Psoriatic Arthritis: Pooled Results From 3 Randomized Clinical Trials Through Up to 2 Years. In: Open Access Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.

Coates, L, Ritchlin, C, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Orbai, A-M, Coates, L, Deodhar, A et al. (9 more authors) (2021) Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Rahman, P, Ritchlin, C, Mease, P et al. (11 more authors) (2021) Long-term Safety of Guselkumab (TREMFYA (R)) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Rahman, P, Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (12 more authors) (2021) Integrated Safety Results of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through the Placebo-Controlled Periods. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Ritchlin, C, Deodhar, A, Boehncke, W-H et al. (10 more authors) (2020) Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naive Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Coates, L, Ritchlin, C, Gossec, L et al. (12 more authors) (2020) Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2020, 05-09 Nov 2021, Virtual.

Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105, Boehncke, W-H et al. (8 more authors) (2020) Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Orbai, A-M, Coates, L, Deodhar, A et al. (8 more authors) (2020) Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Deodhar, A, Helliwell, P, Boencke, W-H et al. (8 more authors) (2020) GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19-SUBUNIT MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO WERE BIOLOGIC-NAIVE OR PRIOR TNF alpha INHIBITOR-TREATED: WEEK 24 RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. In: 22nd PANLAR Congress, 12-15 Aug 2020, Miami, Florida, USA.

Deodhar, A, Helliwell, P, Boehncke, W-H et al. (8 more authors) (2020) P262 Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study. In: British Society for Rheumatology Annual Conference, 20-22 Apr 2020, Online.

Deodhar, A, Helliwell, P, Boencke, W-H et al. (7 more authors) (2019) Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, GA, USA.

Ritchlin, C, Ogdie, A, Giles, J et al. (9 more authors) (2019) Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.